ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Textile Workers at Higher Risk for Rheumatoid Arthritis

Lisa Rapaport  |  February 12, 2016

(Reuters Health)—Breathing textile dust on the job is linked to an almost tripled risk of developing rheumatoid arthritis (RA), a Malaysian study suggests. While smoking is a known risk factor for RA, the findings add to evidence suggesting that environmental factors could trigger RA in some people, the researchers note in their report in Annals…

Filed under:ConditionsRheumatoid ArthritisWorkforce Tagged with:environmentallungMalaysiaRheumatoid Arthritis (RA)Womenworkplace

No Cause Found Yet for Botched French Drug Trial

Reuters Staff  |  February 7, 2016

PARIS (Reuters)—An initial report into a drug trial in northwestern France that left one person dead and five others hospitalized last month did not identify the exact cause, French Health Minister Marisol Touraine said on Thursday. Touraine told a news conference that the condition of the five people who were hospitalized was improving and that…

Filed under:Drug Updates Tagged with:cannabisclinical trialsFranceInternational

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

Filed under:Axial SpondyloarthritisBiologics/DMARDsDrug Updates Tagged with:Ankylosing SpondylitisCelltrion Inc.FDAFood and Drug Administrationinfliximabmonoclonal antibodyRemsimaRheumatoid Arthritis (RA)

The Genetic Factor: Research Examines Genetic Heritability for Pediatric Autoimmune Diseases

Richard Quinn  |  February 5, 2016

Recent research has helped further define genetic heritability for pediatric autoimmune diseases. In an interview, Dr. Hakon Hakanarson discusses how understanding common genetic factors can help develop risk prediction and treatments for such diseases as juvenile idiopathic arthritis, lupus and celiac disease…

Filed under:Conditions Tagged with:Autoimmune diseaseGenetic researchgenetic riskgenomicsPediatric RheumatologyPediatrics

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 3, 2016

An etanercept biosimilar referencing Enbrel and designed to treat multiple autoimmune diseases has been approved for the European market. Also, an application for subcutaneous brodalumab to treat plaque psoriasis has been submitted to the FDA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsbrodalumabetanerceptEuropean UnionFDAFood and Drug Administration

Apremilast Effective for Psoriatic Arthritis

Reuters Staff  |  February 2, 2016

NEW YORK (Reuters Health)—Apremilast improves clinical outcomes in patients with psoriatic arthritis and active psoriasis, according to results from the PALACE 3 randomized controlled trial. Apremilast, a phosphodiesterase 4 (PDE4) inhibitor, showed efficacy against psoriatic arthritis in the PALACE 1 trial. Dr. Christopher J. Edwards from University Hospital Southampton in the U.K. and colleagues evaluated…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:apremilastPsoriasispsoriatic arthritis

Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Laura Newman  |  February 2, 2016

NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularDisease-modifying antirheumatic drugs (DMARDs)Myocardial infarctionnon-TNF biologicsRheumatoid Arthritis (RA)TNFtumor necrosis factor

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  January 27, 2016

Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:combination therapyDisease-modifying antirheumatic drugs (DMARDs)psoriatic arthritisRheumatoid Arthritis (RA)sirukumabTNF inbhibitor

With Genetic Testing Results, More May Be Better

Kathryn Doyle  |  January 26, 2016

(Reuters Health)—When people undergo genetic testing to find out whether they’re at risk for a specific disease, doctors often wonder how much information to give them. What if the genetic testing results reveal a risk for a disease the patient hadn’t been wondering about? Geneticists are “grappling with what to do with all the information…

Filed under:Practice SupportTechnology Tagged with:Alzheimer's DiseaseGenetic researchgenetic riskgenetic testgeneticsTesting

2016 Deadline Imposed by Meaningful Use Program Requires Immediate Attention: Sign Up for 2 Registries by Feb. 29 or Expect Financial Penalty

Kathy Holliman  |  January 25, 2016

Meaningful Use may be changing but it is not going away—yet. Rheumatologists must sign up with two of three registries by Feb. 29 or pay significant financial penalties for not complying with this specific part of the Meaningful Use requirements. The three choices for registries include the Immunization Registry, the Syndromic Surveillance Registry and a…

Filed under:CertificationPractice SupportProfessional Topics Tagged with:Centers for Medicare & Medicaid Services (CMS)Meaningful useregistryRISERISE registry

  • « Previous Page
  • 1
  • …
  • 225
  • 226
  • 227
  • 228
  • 229
  • …
  • 329
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences